Stroke – Pipeline Review, H2 2019

“Global Markets Direct’s, ‘Stroke – Pipeline Review, H2 2019’, provides an overview of the Stroke pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Stroke, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Stroke and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.”

Scope


– The report provides a snapshot of the global therapeutic landscape of Stroke

– The report reviews pipeline therapeutics for Stroke by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Stroke therapeutics and enlists all their major and minor projects

– The report assesses Stroke therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Stroke”

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Stroke

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Stroke pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

“Acorda Therapeutics Inc

Acticor Biotech SAS

Addex Therapeutics Ltd

advanceCor GmbH

AegisCN LLC

Aegle Therapeutics Corp

Affibody AB

Allife Medical Science and Technology Co Ltd

Allosteros Therapeutics Inc

Amarantus Bioscience Holdings Inc

Anavex Life Sciences Corp

Ankasa Regenerative Therapeutics Inc

Annovis Bio Inc

AntiRadical Therapeutics LLC

Antoxis Ltd

Apellis Pharmaceuticals Inc

Aposcience AG

APT Therapeutics Inc

AptaTargets SL

Aranda Pharma Ltd

AriBio

ArmaGen Inc

Aronora Inc

Artelo Biosciences Inc

ArunA Biomedical Inc

Asta Pharmaceuticals Co Ltd

AstraZeneca Plc

Athersys Inc

Avilex Pharma ApS

Axolo Pharma Inc

Band Therapeutics LLC

Beijing Yinfeng Dingcheng Bioengineering Co Ltd

BioAxone BioSciences Inc

Biogen Inc

Boehringer Ingelheim International GmbH

Brain-Gen LLC

Bristol-Myers Squibb Co

CardioVascular BioTherapeutics Inc

Celltrion Inc

Cenyx Biotech Inc

Cerebrum Therapeutics Inc

CHA Bio & Diostech Co Ltd

China Resources Emde Biological Pharmaceutical Co Ltd

Cogentis Therapeutics Inc

CohBar Inc

Constant Therapeutics LLC

CSPC Pharmaceutical Group Ltd

Curacle Co Ltd

CuroNZ Ltd

Daewoong Pharmaceutical Co Ltd

Daiichi Sankyo Co Ltd

Deha Pharmaceutical LLC

DiaMedica Therapeutics Inc

Diffusion Pharmaceuticals Inc

Edvince AB

EIP Pharma LLC

Epigen Biosciences Inc

Epygen Biotech Pvt Ltd

Ever Supreme Bio Technology Co Ltd

Evgen Pharma Plc

eXithera Pharmaceuticals Inc

Exscien Corp

F. Hoffmann-La Roche Ltd

Fortuna Fix Inc

Freeox Biotech SL

Fujifilm Toyama Chemical Co Ltd

GABA Therapeutics Inc

Genervon Biopharmaceuticals LLC

Glialogix Inc

Glucox Biotech AB

GNT Pharma Co Ltd

Guangzhou Cellprotek Pharmaceutical Co Ltd

Guangzhou Magpie Pharmaceutical Co Ltd

Guangzhou Recomgen Biotech Co Ltd

Guangzhou-Sheng Jian Chi Pharmaceutical Co Ltd

Gwoxi Stem Cell Applied Technology Co Ltd

Hefei Industrial Pharmaceutical Institute Co Ltd

Hibernaid Inc

Hillhurst Biopharmaceuticals Inc

Hope Biosciences LLC

HSRx Group

Immunwork Inc

Instituto Biomar SA

International Stem Cell Corp

JCR Pharmaceuticals Co Ltd

Jeil Pharmaceutical Co Ltd

Jiangsu Ouwei Pharmaceutical Co Ltd

JT Pharmaceuticals Inc

Kai Nuo Bio Sci Co Ltd

Kyoto Drug Discovery & Development Co Ltd

Les Laboratoires Servier SAS

Lineage Cell Therapeutics Inc

Living Cell Technologies Ltd

Lixte Biotechnology Holdings Inc

LTT Bio-Pharma Co Ltd

Lumosa Therapeutics Co Ltd

M et P Pharma AG

Mapreg SAS

Marizyme Inc

Meridigen Biotech Co Ltd

Mitoconix Bio Ltd

Modulation Therapeutics Inc

NC Medical Research Inc

NeoCytex Biopharma Inc

NeuExcell Therapeutics Inc

Neuraly Inc

Neuren Pharmaceuticals Ltd

NeurExo Sciences LLC

NeuroActiva Inc

Neurodon LLC

NeuroFix Therapeutics LLC

NeuroNascent Inc

NeurOp Inc

Neurotrope Bioscience Inc

New World Laboratories Inc

Nipro Corp

NoNO Inc

Novago Therapeutics AG

Novartis AG

NuvOx Pharma LLC

Nyrada Inc

Omniox Inc

OTR3 SAS

Paracelsus Neuroscience I LLC

Park Active Molecules

Pharmagenesis Inc

PharmatrophiX Inc

Pharmazz Inc

Pharmicell Co Ltd

Phoenix Biotechnology Inc

PhytoHealth Corp

Prediction BioSciences SAS

Primary Peptides Inc

Q Therapeutics Inc

Regenera Pharma Ltd

Regeneron Pharmaceuticals Inc

RegeneRx Biopharmaceuticals Inc

ReNetX Bio

ReNeuron Group Plc

Rich Pharmaceuticals Inc

Rubicon Biotechnology Inc

Saje Pharma LLC

SanBio Inc

Saneron CCEL Therapeutics Inc

Saniona AB

Sansho Co Ltd

Savara Inc

Seneca Biopharma Inc

Sentan Pharma Inc

Shanghai Angecon Biotechnology Corp

Shanghai SIMR Biotech Co Ltd

Shin Poong Pharm Co Ltd

Shionogi & Co Ltd

Simcere Pharmaceutical Group

Stemedica Cell Technologies Inc

Stemetix Inc

Stream Biomedical Inc

SunBio Inc

Suzhou Pharmavan Cancer Research Center Co Ltd

TaiGen Biotechnology Co Ltd

Tasly Pharmaceutical Group Co Ltd

Techfields Pharma Co Ltd

Tenax Therapeutics Inc

The Cell Factory BVBA

TheraSource LLC

Theratome Bio Inc

Thrombolytic Science International LLC

TikoMed AB

TMS Co Ltd

Translational Sciences Inc

Valin Technologies Ltd

Vect-Horus SAS

Verseon Corp

Virogenomics BioDevelopment Inc

Virtici LLC

WhanIn Pharmaceutical Co Ltd

Xcelthera INC

Xonovo Inc

Yantai YenePharma Co Ltd

Zensun (Shanghai) Sci & Tech Co Ltd

Zhejiang Ausun Pharmaceutical Co Ltd

Zocere Inc

ZyVersa Therapeutics Inc

ZZ Biotech LLC”

Table of Contents

Table of Contents

Table of Contents 2

Introduction 7

Stroke Overview 8

Stroke Therapeutics Development 9

Stroke Therapeutics Assessment 34

Stroke Companies Involved in Therapeutics Development 50

Stroke Drug Profiles 91

Stroke Dormant Projects 495

Stroke Discontinued Products 508

Stroke Product Development Milestones 511

Appendix 522

List of Tables

“List of Tables

Table 1: Number of Products under Development for Stroke, H2 2019

Table 2: Number of Products under Development by Companies, H2 2019

Table 3: Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Table 4: Number of Products under Development by Companies, H2 2019 (Contd..2), H2 2019

Table 5: Number of Products under Development by Companies, H2 2019 (Contd..3), H2 2019

Table 6: Number of Products under Development by Companies, H2 2019 (Contd..4), H2 2019

Table 7: Number of Products under Development by Companies, H2 2019 (Contd..5), H2 2019

Table 8: Number of Products under Development by Companies, H2 2019 (Contd..6), H2 2019

Table 9: Number of Products under Development by Companies, H2 2019 (Contd..7), H2 2019

Table 10: Number of Products under Development by Companies, H2 2019 (Contd..8), H2 2019

Table 11: Number of Products under Development by Companies, H2 2019 (Contd..9), H2 2019

Table 12: Number of Products under Development by Universities/Institutes, H2 2019

Table 13: Number of Products under Development by Universities/Institutes, H2 2019 (Contd..1), H2 2019

Table 14: Products under Development by Companies, H2 2019

Table 15: Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Table 16: Products under Development by Companies, H2 2019 (Contd..2), H2 2019

Table 17: Products under Development by Companies, H2 2019 (Contd..3), H2 2019

Table 18: Products under Development by Companies, H2 2019 (Contd..4), H2 2019

Table 19: Products under Development by Companies, H2 2019 (Contd..5), H2 2019

Table 20: Products under Development by Companies, H2 2019 (Contd..6), H2 2019

Table 21: Products under Development by Companies, H2 2019 (Contd..7), H2 2019

Table 22: Products under Development by Companies, H2 2019 (Contd..8), H2 2019

Table 23: Products under Development by Companies, H2 2019 (Contd..9), H2 2019

Table 24: Products under Development by Companies, H2 2019 (Contd..10), H2 2019

Table 25: Products under Development by Companies, H2 2019 (Contd..11), H2 2019

Table 26: Products under Development by Universities/Institutes, H2 2019

Table 27: Products under Development by Universities/Institutes, H2 2019 (Contd..1), H2 2019

Table 28: Number of Products by Stage and Target, H2 2019

Table 29: Number of Products by Stage and Target, H2 2019 (Contd..1), H2 2019

Table 30: Number of Products by Stage and Target, H2 2019 (Contd..2), H2 2019

Table 31: Number of Products by Stage and Target, H2 2019 (Contd..3), H2 2019

Table 32: Number of Products by Stage and Target, H2 2019 (Contd..4), H2 2019

Table 33: Number of Products by Stage and Target, H2 2019 (Contd..5), H2 2019

Table 34: Number of Products by Stage and Mechanism of Action, H2 2019

Table 35: Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..1), H2 2019

Table 36: Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..2), H2 2019

Table 37: Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..3), H2 2019

Table 38: Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..4), H2 2019

Table 39: Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..5), H2 2019

Table 40: Number of Products by Stage and Route of Administration, H2 2019

Table 41: Number of Products by Stage and Molecule Type, H2 2019

Table 42: Stroke – Pipeline by Acorda Therapeutics Inc, H2 2019

Table 43: Stroke – Pipeline by Acticor Biotech SAS, H2 2019

Table 44: Stroke – Pipeline by Addex Therapeutics Ltd, H2 2019

Table 45: Stroke – Pipeline by advanceCor GmbH, H2 2019

Table 46: Stroke – Pipeline by AegisCN LLC, H2 2019

Table 47: Stroke – Pipeline by Aegle Therapeutics Corp, H2 2019

Table 48: Stroke – Pipeline by Affibody AB, H2 2019

Table 49: Stroke – Pipeline by Allife Medical Science and Technology Co Ltd, H2 2019

Table 50: Stroke – Pipeline by Allosteros Therapeutics Inc, H2 2019

Table 51: Stroke – Pipeline by Amarantus Bioscience Holdings Inc, H2 2019

Table 52: Stroke – Pipeline by Anavex Life Sciences Corp, H2 2019

Table 53: Stroke – Pipeline by Ankasa Regenerative Therapeutics Inc, H2 2019

Table 54: Stroke – Pipeline by Annovis Bio Inc, H2 2019

Table 55: Stroke – Pipeline by AntiRadical Therapeutics LLC, H2 2019

Table 56: Stroke – Pipeline by Antoxis Ltd, H2 2019

Table 57: Stroke – Pipeline by Apellis Pharmaceuticals Inc, H2 2019

Table 58: Stroke – Pipeline by Aposcience AG, H2 2019

Table 59: Stroke – Pipeline by APT Therapeutics Inc, H2 2019

Table 60: Stroke – Pipeline by AptaTargets SL, H2 2019”

List of Figures

“List of Figures

Figure 1: Number of Products under Development for Stroke, H2 2019

Figure 2: Number of Products under Development by Companies, H2 2019

Figure 3: Number of Products under Development by Universities/Institutes, H2 2019

Figure 4: Number of Products by Top 10 Targets, H2 2019

Figure 5: Number of Products by Stage and Top 10 Targets, H2 2019

Figure 6: Number of Products by Top 10 Mechanism of Actions, H2 2019

Figure 7: Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019

Figure 8: Number of Products by Top 10 Routes of Administration, H2 2019

Figure 9: Number of Products by Stage and Top 10 Routes of Administration, H2 2019

Figure 10: Number of Products by Top 10 Molecule Types, H2 2019

Figure 11: Number of Products by Stage and Top 10 Molecule Types, H2 2019”

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports